Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Chronic obstructive pulmonary disease is associated with a low grade systemic inflammatory
process. Systemic inflammation is hypothesized to maintain cardiovascular morbidity and
mortality in COPD. Early changes of vascular integrity can be detected via markers of
subclinical atherosclerosis.
Selective Inhibition of phosphodiesterase subtype 4 describes a promising therapeutic option
in COPD with beneficial impact on lung function and exacerbation rate. Moreover, an
anti-inflammatory effect of phosphodiesterase-4 inhibition was confirmed by recent data.
The aim of this study is to assess the effects of the phosphodiesterase-4 inhibitor
Roflumilast on firstly surrogates of subclinical atherosclerosis and secondly markers of
systemic inflammation in the peripheral circulation of patients with stable chronic
obstructive pulmonary disease.
Phase:
Phase 4
Details
Lead Sponsor:
LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology